Talazoparib Approved in Europe for BRCA-Mutant Breast Cancer

June 21, 2019 – The European Commission has approved single-agent talazoparib for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer. The approval is based on findings from the phase III EMBRACA study, in which talazoparib led to a 46% reduction in the risk of disease progression a median compared with standard chemotherapy in patients with germline BRCA1/2-mutant, HER2-negative … (leggi tutto)